United Therapeutics Corporation (NASDAQ:UTHR)‘s stock had its “buy” rating restated by investment analysts at Oppenheimer Holdings, Inc. in a note issued to investors on Friday.

A number of other equities analysts also recently issued reports on UTHR. Jefferies Group LLC restated a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. ValuEngine downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Friday. BidaskClub downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. UBS AG restated a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Finally, Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Six research analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the stock. United Therapeutics Corporation has a consensus rating of “Hold” and an average target price of $134.50.

United Therapeutics Corporation (NASDAQ UTHR) traded down 0.128% during trading on Friday, hitting $120.665. The stock had a trading volume of 414,272 shares. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 13.993 and a beta of 1.52. The company has a 50-day moving average of $130.11 and a 200 day moving average of $130.47. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. During the same quarter last year, the business earned $4.42 earnings per share. United Therapeutics Corporation’s revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Corporation will post $10.09 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/11/united-therapeutics-corporation-uthr-rating-reiterated-by-oppenheimer-holdings-inc.html.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,238 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $130.20, for a total value of $161,187.60. Following the completion of the sale, the chief executive officer now owns 1,378 shares of the company’s stock, valued at $179,415.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond Dwek sold 3,490 shares of the firm’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $131.71, for a total value of $459,667.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,178 shares of company stock valued at $3,289,427. 7.80% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. HPM Partners LLC grew its stake in United Therapeutics Corporation by 0.8% in the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 15 shares during the period. First Allied Advisory Services Inc. grew its stake in United Therapeutics Corporation by 0.4% in the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after acquiring an additional 19 shares during the period. Nomura Asset Management Co. Ltd. grew its stake in United Therapeutics Corporation by 0.3% in the first quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock valued at $1,712,000 after acquiring an additional 40 shares during the period. Fisher Asset Management LLC grew its stake in United Therapeutics Corporation by 1.4% in the second quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock valued at $411,000 after acquiring an additional 45 shares during the period. Finally, Argent Capital Management LLC grew its stake in United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock valued at $343,000 after acquiring an additional 60 shares during the period.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.